Rui Andre Nunes dos Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rui Andre Nunes dos Santos has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Amy Trebes
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford, Old Road Campus, Oxford OX3 7BN, UK
1 shared publication Andrew Nelson
Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, UK
1 shared publication- Andrew Nelson
Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, NE1 8ST, UK
1 shared publication Anel Nurtay
Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK
1 shared publicationAngie Green
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Biomedical Research Centre, University of Oxford, Oxford, UK
1 shared publicationAnn Sarah Walker
Nuffield Department of Medicine, University of Oxford, Oxford, UK
1 shared publication
Latest Publications
- Open Access
- 10 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Microbiome and immune development in preterm infants receiving powdered human milk‐based fortification from the PUFFIN trial
Objective: To determine the impact of powdered human milk‐based fortification (PHMF) compared to powdered bovine milk‐based fortification on gut microbiome and inflammation in preterm infants. Methods: Mechanistic study within randomised controlled trial in infants p = 0.04; 25.7% at D21, p = 0.007). Stool but not urine sIgA was higher in PHMF recipients. Whilst fortifier type was not associated with IRPs from D7 to D21, NICU site impacted IRPs. Conclusions: Fortifier type did not have a large impact on microbiota or IRPs but stool sIgA was higher in PHMF recipients. An association between NICU site and other outcomes was observed. Trial Registration: ClinicalTrials.gov identifier: The Preterm milk fortification in neonates (PUFFIN) study was prospectively registered ISRCTN 22484792.
- 10 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Open AccessMicrobiome and immune development in preterm infants receiving powdered human milk‐based fortification from the PUFFIN trial
Objective: To determine the impact of powdered human milk‐based fortification (PHMF) compared to powdered bovine milk‐based fortification on gut microbiome and inflammation in preterm infants. Methods: Mechanistic study within randomised controlled trial in infants p = 0.04; 25.7% at D21, p = 0.007). Stool but not urine sIgA was higher in PHMF recipients. Whilst fortifier type was not associated with IRPs from D7 to D21, NICU site impacted IRPs. Conclusions: Fortifier type did not have a large impact on microbiota or IRPs but stool sIgA was higher in PHMF recipients. An association between NICU site and other outcomes was observed. Trial Registration: ClinicalTrials.gov identifier: The Preterm milk fortification in neonates (PUFFIN) study was prospectively registered ISRCTN 22484792.
- Top Cited PapersOpen Access
- 21 February 2024
- Published by Springer Nature in Nature
- Vol. 626 (8001) , 1094-1101
Prevalence of persistent SARS-CoV-2 in a large community surveillance study
Persistent SARS-CoV-2 infections may act as viral reservoirs that could seed future outbreaks1–5, give rise to highly divergent lineages6–8 and contribute to cases with post-acute COVID-19 sequelae (long COVID)9,10. However, the population prevalence of persistent infections, their viral load kinetics and evolutionary dynamics over the course of infections remain largely unknown. Here, using viral sequence data collected as part of a national infection survey, we identified 381 individuals with SARS-CoV-2 RNA at high titre persisting for at least 30 days, of which 54 had viral RNA persisting at least 60 days. We refer to these as ‘persistent infections’ as available evidence suggests that they represent ongoing viral replication, although the persistence of non-replicating RNA cannot be ruled out in all. Individuals with persistent infection had more than 50% higher odds of self-reporting long COVID than individuals with non-persistent infection. We estimate that 0.1–0.5% of infections may become persistent with typically rebounding high viral loads and last for at least 60 days. In some individuals, we identified many viral amino acid substitutions, indicating periods of strong positive selection, whereas others had no consensus change in the sequences for prolonged periods, consistent with weak selection. Substitutions included mutations that are lineage defining for SARS-CoV-2 variants, at target sites for monoclonal antibodies and/or are commonly found in immunocompromised people11–14. This work has profound implications for understanding and characterizing SARS-CoV-2 infection, epidemiology and evolution.
- 21 February 2024
- Published by Springer Nature in Nature
- Vol. 626 (8001) , 1094-1101
Top Cited PapersOpen AccessPrevalence of persistent SARS-CoV-2 in a large community surveillance study
Persistent SARS-CoV-2 infections may act as viral reservoirs that could seed future outbreaks1–5, give rise to highly divergent lineages6–8 and contribute to cases with post-acute COVID-19 sequelae (long COVID)9,10. However, the population prevalence of persistent infections, their viral load kinetics and evolutionary dynamics over the course of infections remain largely unknown. Here, using viral sequence data collected as part of a national infection survey, we identified 381 individuals with SARS-CoV-2 RNA at high titre persisting for at least 30 days, of which 54 had viral RNA persisting at least 60 days. We refer to these as ‘persistent infections’ as available evidence suggests that they represent ongoing viral replication, although the persistence of non-replicating RNA cannot be ruled out in all. Individuals with persistent infection had more than 50% higher odds of self-reporting long COVID than individuals with non-persistent infection. We estimate that 0.1–0.5% of infections may become persistent with typically rebounding high viral loads and last for at least 60 days. In some individuals, we identified many viral amino acid substitutions, indicating periods of strong positive selection, whereas others had no consensus change in the sequences for prolonged periods, consistent with weak selection. Substitutions included mutations that are lineage defining for SARS-CoV-2 variants, at target sites for monoclonal antibodies and/or are commonly found in immunocompromised people11–14. This work has profound implications for understanding and characterizing SARS-CoV-2 infection, epidemiology and evolution.